This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Haematuria

Authoring team

Haematuria is the presence of red blood cells in the urine. It can either be:

  • visible haematuria (VH) - also referred to as macroscopic haematuria or gross haematuria
  • non visible haematuria (NVH) - also known as microscopic haematuria or ‘dipstick positive haematuria’ (1)

Significant haematuria is defined as:

  • any single episode of VH
  • any single episode of symptomatic -NVH (in absence of UTI or other transient causes).
  • persistent asymptomatic -NVH (in absence of UTI or other transient causes). Persistence is defined as 2 out of 3 dipsticks positive for NVH(1)

NICE state (3)

  • refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for bladder cancer if they are:
    • aged 45 and over and have:
      • unexplained visible haematuria without urinary tract infection or
      • visible haematuria that persists or recurs after successful treatment of urinary tract infection, or
      • aged 60 and over and have unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test

    • consider non-urgent referral for bladder cancer in people aged 60 and over with recurrent or persistent unexplained urinary tract infection

Note:

  • presence of haematuria (VH or NVH) should not be attributed to anti-coagulant or anti-platelet therapy and patients should be evaluated regardless of these medications (1).

Reference:

  1. Renal Association and British Association of Urological Surgeons (2008). Joint Consensus Statement on the Initial Assessment of Haematuria
  2. Rodgers M et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation; Health Technology Assessment 2006;10(18)
  3. NICE. Suspected cancer: recognition and referral. NICE guideline NG12. Published June 2015, last updated October 2023.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.